Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Velcade Gx Skips Listing, Teva Takeda Says Not Ready for Launch
June 15, 2018
- Eisai Enters Agreement with 6 Institutions for Nucleic Acid Drug Discovery Research; Project Selected for CiCLE Program
June 14, 2018
- Univ. of Tokyo, Fujitsu, Kowa Discover Novel Small Molecule Compounds Using IT-Based Drug Discovery
June 14, 2018
- US FDA Accepts NDA for Sunovion’s Parkinson’s Disease Treatment
June 14, 2018
- Eisai to Launch New US Research Center for Innovative Drug Discovery in Dementia Field
June 14, 2018
- Mochida Licenses EPA Technologies to Amarin
June 13, 2018
- EA Pharma Licenses SHPT Treatment to China Firm
June 13, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Ethical Drug Sales Jump 7.6% in April on Price Revision: Crecon
June 12, 2018
- Parkinson’s Drug Azilect Now Available in Japan: Takeda
June 12, 2018
- Vortioxetine Showed Positive Results in Japan PIII with MDD Patients: Takeda/Lundbeck
June 12, 2018
- Biogen Enters Exclusive Option Agreement for Acute Stroke Treatment with Japanese Biotech
June 12, 2018
- Astellas Launches Tablet Formulations of Xtandi
June 12, 2018
- Takeda Inks US$7.5 billion Term Loan Credit to Refinance M&A Bridge
June 11, 2018
- FY2017 Earnings Roundup - 4: Japan Makers Struggling to Recoup R&D Investments, New Value-Generating Model Is a Must
June 8, 2018
- Bayer Establishes Asia’s 1st “CoLaborator” in Kobe for Use by Startups
June 8, 2018
- FY2017 Earnings Roundup - 3: Top 3 Japan Generic Makers Pursuing Diversified Overseas Strategies
June 7, 2018
- Shionogi’s Single-Dose Flu Med Xofluza Heavily Promoted in March: Anterio
June 7, 2018
- Olmesartan Lawsuit Settlement in US Now Valid: Daiichi Sankyo
June 7, 2018
- Nobelpharma’s Rapalimus Now Available in Japan
June 7, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…